Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of New York Mellon Corp grew its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 33.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 450,261 shares of the company’s stock after buying an additional 111,989 shares during the period. Bank of New York Mellon Corp owned 0.22% of Taysha Gene Therapies worth $779,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TSHA. Intech Investment Management LLC purchased a new position in Taysha Gene Therapies during the 3rd quarter valued at $85,000. MetLife Investment Management LLC increased its position in shares of Taysha Gene Therapies by 81.9% during the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock valued at $153,000 after buying an additional 34,243 shares during the period. Franklin Resources Inc. purchased a new position in shares of Taysha Gene Therapies during the third quarter valued at about $201,000. Barclays PLC raised its stake in Taysha Gene Therapies by 356.0% in the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after buying an additional 193,046 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Taysha Gene Therapies by 7.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after buying an additional 33,123 shares during the period. Institutional investors own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TSHA. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $1.77 on Wednesday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $362.85 million, a P/E ratio of 2.81 and a beta of 0.91. The business’s 50 day moving average price is $1.64 and its 200-day moving average price is $1.92. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.